# Icaritin Soft Capsule Combined With Lenvatinib and TACE for the Treatment of Hepatocellular Carcinoma

> **NCT05903456** · PHASE2 · UNKNOWN · sponsor: **Zhejiang Cancer Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **PROCEDURE:** TACE（transcatheter arterial chemoembolization）
- **DRUG:** lenvatinib
- **DRUG:** Icaritin soft capsules

## Key facts

- **NCT ID:** NCT05903456
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-07
- **Primary completion:** 2025-05
- **Final completion:** 2025-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05903456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05903456, "Icaritin Soft Capsule Combined With Lenvatinib and TACE for the Treatment of Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05903456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*